2. Amyotrophic lateral sclerosis Clinical trials / Disease details
Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01551940 (ClinicalTrials.gov) | February 2012 | 9/3/2012 | Toxin Treatment for Amyotrophic Lateral Sclerosis (ALS) Related Sialorrhea | Evaluation of Efficacy of Botulinum Toxin Type A in the Treatment of Sialorrhea in the Patient Affected by Amyotrophic Lateral Sclerosis (ALS) | Sialorrhea;Amyotrophic Lateral Sclerosis | Drug: Botox injection;Drug: Placebo injection | Hospices Civils de Lyon | NULL | Completed | 18 Years | N/A | Both | 18 | Phase 2 | France |
| 2 | EUCTR2010-023161-21-FR (EUCTR) | 23/11/2011 | 06/09/2011 | Sclérose Latérale Amyotrophique (SLA) – toxine botulinique A (Botox®) | Evaluation de la toxine botulinique dans le traitement du trouble salivaire chez le patient atteint de sclérose latérale amyotrophique - SLA-TOX | Sclérose Latérale Amyotrophique (SLA) MedDRA version: 14.0;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: BOTOX 100 UNITES ALLERGAN (PR1) Other descriptive name: BOTULINUM TOXIN TYPE A | Hospices Civils de Lyon | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Phase 2 | France |